肝硬化患者凝血四项、D-二聚体水平及AT-Ⅲ的表达及临床意义
|
摘要
目的探讨检测凝血四项、D-二聚体水平与抗凝血酶(AT-Ⅲ)对评价肝硬化患者疾病状况的价值。方法选择2016年2月～2018年7月我院收治的51例肝硬化患者为观察组,50例健康体检者为对照组,对两组研究对象的凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、凝血酶时间(TT)、D-二聚体及AT-Ⅲ指标水平进行检测。结果观察组患者PT、APTT及TT均较对照组明显延长,FIB的含量较对照组低,差异具有统计学意义(P<0.05);在D-二聚体上观察组高于对照组,AT-Ⅲ上观察组低于对照组,差异有统计学意义(P<0.05);肝硬化患者随着病情的加重,PT、APTT、TT及D-二聚体呈逐渐上升趋势,而FIB、AT-Ⅲ呈逐渐下降趋势。结论针对肝硬化患者,对其凝血四项、D-二聚体及AT-Ⅲ指标水平进行检测,可以客观的评价患者的凝血状况,值得推广。
Objective To investigate the value of detecting four items of blood coagulation, D-dimer and anti-thrombin(AT-III) in evaluating the disease status of patients with liver cirrhosis. Methods 51 patients with cirrhosis admitted in our hospital from February 2016 to July 2018 were included in the observation group, and 50 healthy subjects were selected as the control group. Prothrombin time(PT), activated partial thromboplastin time(APTT), fibrinogen(FIB), thrombin time(TT), D-dimer, and AT-Ⅲ of two groups were measured. Results The PT, APTT and TT of the observation group were significantly longer than those of the control group. The content of FIB in the observation group was lower than that of the control group, and the difference was statistically significant(P<0.05). The D-dimer of the observation group was higher than that of the control group. The AT-Ⅲ of the observation group was lower than that of the control group,and the difference was also statistically significant(P<0.05). The PT, APTT, TT and D-dimer showed a gradual increase with the aggravation of the disease in patients with liver cirrhosis, while FIB and AT-III showed a gradual decline.Conclusion For patients with cirrhosis, the detection of four items of coagulation, D-dimer and AT-III can objectively evaluate the coagulation status of patients and is worth promoting.
Objective To investigate the value of detecting four items of blood coagulation, D-dimer and anti-thrombin(AT-III) in evaluating the disease status of patients with liver cirrhosis. Methods 51 patients with cirrhosis admitted in our hospital from February 2016 to July 2018 were included in the observation group, and 50 healthy subjects were selected as the control group. Prothrombin time(PT), activated partial thromboplastin time(APTT), fibrinogen(FIB), thrombin time(TT), D-dimer, and AT-Ⅲ of two groups were measured. Results The PT, APTT and TT of the observation group were significantly longer than those of the control group. The content of FIB in the observation group was lower than that of the control group, and the difference was statistically significant(P<0.05). The D-dimer of the observation group was higher than that of the control group. The AT-Ⅲ of the observation group was lower than that of the control group,and the difference was also statistically significant(P<0.05). The PT, APTT, TT and D-dimer showed a gradual increase with the aggravation of the disease in patients with liver cirrhosis, while FIB and AT-III showed a gradual decline.Conclusion For patients with cirrhosis, the detection of four items of coagulation, D-dimer and AT-III can objectively evaluate the coagulation status of patients and is worth promoting.
引文
[1]杨倩.凝血四项及AT-Ⅲ、D-二聚体在肝硬化患者中的变化及临床意义[J].检验医学与临床,2015,6(22):3371-3372.
[2]马维兰,康海虎,马正军.老年肝硬化病人凝血四项与抗凝血酶Ⅲ、D-二聚体的水平变化及意义[J].实用老年医学,2017,23(9):879-880.
[3]刘小书.妊娠晚期女性凝血四项、纤维蛋白(原)降解产物及D-二聚体水平变化及临床意义[J].中国妇幼保健,2017,32(15):3454-3456.
[4]董晓玉.联合检测凝血四项、D二聚体、纤维蛋白/纤维蛋白原降解产物对肝病患者的临床价值[J].血栓与止血学,2016,22(3):283-285.
[5]肖强,杨善峰.乙型肝炎肝硬化患者血清D-二聚体、纤维蛋白原及抗凝血酶-Ⅲ的测定意义[J].实用肝脏病杂志,2011,14(3):214-215.
[6]邓芝云,张艳,肖娜娜,等.凝血四项与D-二聚体检测在肝硬化患者中的临床观察分析[J].西北国防医学杂志,2013,14(6):519-520.
[7]覃平良.凝血四项及D-二聚体检测在肝硬化患者中的应用探析[J].中国继续医学教育,2016,8(2):56-57.
[8]闫伟华,张国秀.D二聚体及凝血四项在急性百草枯中毒肺损伤中的表达及意义分析[J].临床研究,2016,22(1):202-202.
[9]马妍艳.凝血四项在肝硬化诊断中的应用及价值探析[J]中国医药科学,2015,5(13):211-212,217.
[10]杨波.凝血四项及AT-Ⅲ、D-二聚体在肝硬化患者中的变化及临床意义[J].河南医学研究,2017,23(1):24-26.
[11]杨良,杨斌,黄夏逸.肝硬化患者血浆纤维蛋白原、D-二聚体和抗凝血酶Ⅲ活性检测及临床意义[J].检验医学与临床,2017,14(A2):272-274.
[12]刘阳桦,吴敏.细菌性血流感染所致脓毒症患者凝血-炎症生物标志物水平变化的临床意义[J].中国病原生物学杂志,2017,17(3):84-87.
[13]郝德彦,宋志,孟兴凯.经肝动脉自体骨髓干细胞肝内移植治疗对失代偿期肝硬化临床效果、肝功能及凝血指标的影响[J].中国医药导报,2018,15(35):126-129.
[14]袁成立.纤维蛋白原、活化部分凝血活酶时间、凝血酶原时间、凝血酶时间、D-二聚体检测对评定肝硬化患者肝损伤程度的意义[J].吉林医学,2018,27(5):61-64.
[15]陈峰,刘安,贾小芳,等.连续性血液净化对小儿脓毒症患者血清抗凝血酶Ⅲ,IL-6及D-二聚体水平的影响[J].现代生物医学进展,2016,16(33):6529-6532.
[2]马维兰,康海虎,马正军.老年肝硬化病人凝血四项与抗凝血酶Ⅲ、D-二聚体的水平变化及意义[J].实用老年医学,2017,23(9):879-880.
[3]刘小书.妊娠晚期女性凝血四项、纤维蛋白(原)降解产物及D-二聚体水平变化及临床意义[J].中国妇幼保健,2017,32(15):3454-3456.
[4]董晓玉.联合检测凝血四项、D二聚体、纤维蛋白/纤维蛋白原降解产物对肝病患者的临床价值[J].血栓与止血学,2016,22(3):283-285.
[5]肖强,杨善峰.乙型肝炎肝硬化患者血清D-二聚体、纤维蛋白原及抗凝血酶-Ⅲ的测定意义[J].实用肝脏病杂志,2011,14(3):214-215.
[6]邓芝云,张艳,肖娜娜,等.凝血四项与D-二聚体检测在肝硬化患者中的临床观察分析[J].西北国防医学杂志,2013,14(6):519-520.
[7]覃平良.凝血四项及D-二聚体检测在肝硬化患者中的应用探析[J].中国继续医学教育,2016,8(2):56-57.
[8]闫伟华,张国秀.D二聚体及凝血四项在急性百草枯中毒肺损伤中的表达及意义分析[J].临床研究,2016,22(1):202-202.
[9]马妍艳.凝血四项在肝硬化诊断中的应用及价值探析[J]中国医药科学,2015,5(13):211-212,217.
[10]杨波.凝血四项及AT-Ⅲ、D-二聚体在肝硬化患者中的变化及临床意义[J].河南医学研究,2017,23(1):24-26.
[11]杨良,杨斌,黄夏逸.肝硬化患者血浆纤维蛋白原、D-二聚体和抗凝血酶Ⅲ活性检测及临床意义[J].检验医学与临床,2017,14(A2):272-274.
[12]刘阳桦,吴敏.细菌性血流感染所致脓毒症患者凝血-炎症生物标志物水平变化的临床意义[J].中国病原生物学杂志,2017,17(3):84-87.
[13]郝德彦,宋志,孟兴凯.经肝动脉自体骨髓干细胞肝内移植治疗对失代偿期肝硬化临床效果、肝功能及凝血指标的影响[J].中国医药导报,2018,15(35):126-129.
[14]袁成立.纤维蛋白原、活化部分凝血活酶时间、凝血酶原时间、凝血酶时间、D-二聚体检测对评定肝硬化患者肝损伤程度的意义[J].吉林医学,2018,27(5):61-64.
[15]陈峰,刘安,贾小芳,等.连续性血液净化对小儿脓毒症患者血清抗凝血酶Ⅲ,IL-6及D-二聚体水平的影响[J].现代生物医学进展,2016,16(33):6529-6532.